Foursixthree Capital LP Arbutus Biopharma Corp Transaction History
Foursixthree Capital LP
- $364 Billion
- Q3 2025
A detailed history of Foursixthree Capital LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Foursixthree Capital LP holds 1,978,975 shares of ABUS stock, worth $8.94 Million. This represents 2.47% of its overall portfolio holdings.
Number of Shares
1,978,975
Previous 2,557,367
22.62%
Holding current value
$8.94 Million
Previous $7.9 Billion
13.7%
% of portfolio
2.47%
Previous 2.76%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
194Shares Held
118MCall Options Held
2.67MPut Options Held
693K-
Morgan Stanley New York, NY24.5MShares$111 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$60.3 Million22.38% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$52.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY11MShares$49.7 Million0.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.99MShares$40.6 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $678M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...